vs
Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $73.3M, roughly 1.0× Apollo Commercial Real Estate Finance, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 4.0%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -4.6%).
Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
ARI vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $73.3M | $75.5M |
| Net Profit | $29.2M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 39.7% | 22.7% |
| Net Margin | 39.9% | — |
| Revenue YoY | 4.0% | 27.7% |
| Net Profit YoY | -28.2% | — |
| EPS (diluted) | $0.19 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $73.3M | $75.5M | ||
| Q3 25 | $61.6M | $54.5M | ||
| Q2 25 | $70.9M | $52.4M | ||
| Q1 25 | $65.8M | $46.0M | ||
| Q4 24 | $70.5M | $59.1M | ||
| Q3 24 | $71.6M | $80.5M | ||
| Q2 24 | $81.1M | $47.1M | ||
| Q1 24 | $80.5M | $43.8M |
| Q4 25 | $29.2M | — | ||
| Q3 25 | $50.8M | $8.8M | ||
| Q2 25 | $20.7M | $5.9M | ||
| Q1 25 | $26.0M | $3.0M | ||
| Q4 24 | $40.7M | — | ||
| Q3 24 | $-91.5M | $20.3M | ||
| Q2 24 | $35.8M | $-4.5M | ||
| Q1 24 | $-104.5M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 39.7% | 22.7% | ||
| Q3 25 | 82.8% | 17.6% | ||
| Q2 25 | 29.4% | 12.7% | ||
| Q1 25 | 39.7% | 8.7% | ||
| Q4 24 | 57.9% | 22.6% | ||
| Q3 24 | -127.8% | 27.4% | ||
| Q2 24 | 44.2% | -4.6% | ||
| Q1 24 | -129.6% | -5.3% |
| Q4 25 | 39.9% | — | ||
| Q3 25 | 82.4% | 16.2% | ||
| Q2 25 | 29.3% | 11.2% | ||
| Q1 25 | 39.5% | 6.5% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -127.9% | 25.2% | ||
| Q2 24 | 44.1% | -9.6% | ||
| Q1 24 | -129.8% | -11.0% |
| Q4 25 | $0.19 | $0.26 | ||
| Q3 25 | $0.34 | $0.17 | ||
| Q2 25 | $0.12 | $0.12 | ||
| Q1 25 | $0.16 | $0.06 | ||
| Q4 24 | $0.25 | $0.40 | ||
| Q3 24 | $-0.69 | $0.41 | ||
| Q2 24 | $0.23 | $-0.09 | ||
| Q1 24 | $-0.76 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $139.8M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.9B | $130.3M |
| Total Assets | $9.9B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $139.8M | $97.5M | ||
| Q3 25 | $245.9M | $94.4M | ||
| Q2 25 | $177.6M | $96.0M | ||
| Q1 25 | $166.4M | $93.2M | ||
| Q4 24 | $317.4M | $101.0M | ||
| Q3 24 | $194.3M | $96.7M | ||
| Q2 24 | $174.7M | $96.8M | ||
| Q1 24 | $161.2M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $1.9B | $130.3M | ||
| Q3 25 | $1.9B | $115.3M | ||
| Q2 25 | $1.8B | $104.7M | ||
| Q1 25 | $1.9B | $97.1M | ||
| Q4 24 | $1.9B | $92.1M | ||
| Q3 24 | $1.9B | $71.1M | ||
| Q2 24 | $2.0B | $48.5M | ||
| Q1 24 | $2.0B | $51.0M |
| Q4 25 | $9.9B | $216.3M | ||
| Q3 25 | $9.5B | $202.9M | ||
| Q2 25 | $9.8B | $194.9M | ||
| Q1 25 | $8.8B | $196.2M | ||
| Q4 24 | $8.4B | $213.3M | ||
| Q3 24 | $9.1B | $220.7M | ||
| Q2 24 | $9.3B | $205.0M | ||
| Q1 24 | $9.2B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.5M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 4.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $142.5M | $14.4M | ||
| Q3 25 | $31.7M | $9.7M | ||
| Q2 25 | $63.2M | $14.1M | ||
| Q1 25 | $39.3M | $3.6M | ||
| Q4 24 | $200.3M | $15.6M | ||
| Q3 24 | $47.2M | $11.0M | ||
| Q2 24 | $50.2M | $1.0M | ||
| Q1 24 | $52.8M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 4.88× | — | ||
| Q3 25 | 0.62× | 1.10× | ||
| Q2 25 | 3.05× | 2.41× | ||
| Q1 25 | 1.51× | 1.21× | ||
| Q4 24 | 4.93× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
